Assistant Professor, Division of Respiratory Medicine, UBC-VCH
phone: 6048754111
fax: 6048754013

Nitric Oxide Research Lab

Immune cells in the body produce Nitric Oxide (NO) in response to bacteria and viruses. My research group studies the antimicrobial properties of NO and has found that this naturally produced molecule can be used as an effective non-specific antimicrobial agent against a broad range of microorganisms, including gram positive, gram negative and multi-drug resistant strains of bacteria, yeast, viruses, and mycobacteria.

I am focused on establishing a Nitric Oxide Research Program at the University of British Columbia’s Department of Medicine, with the goal of developing NO as a potential treatment for infections such as tuberculosis, malaria, leishmaniasis, cystic fibrosis, and as a first line treatment for viral pandemics. The cornerstone of this effort has been generously provided through a highly sought after, but rarely obtained, United States Defense Advanced Research Projects Agency (DARPA) Grant for my project entitled, “Nitric Oxide for Prevention and Treatment of Pandemic Flu.”

Scholarly Interests

  • Antimicrobial role of nitric oxide
  • Antibiotic resistance associated with M. tuberculosis, S. aureus, P. aeruginosa
  • Role of nitric oxide in non-healing wounds and cystic fibrosis
  • Therapeutic use of nitric oxide in Avian flu and parasitic infections
  • Inhaled nitric oxide for treatment of cerebral malaria (http://www.youtube.com/user/iNOUganda)
  • Tumorcidal activity of nitric oxide
  • Chronic sinusitis
  • Ventilator acquired pneumonia

Recent Publications

Refereed Publications

Regev-Shoshani G, McMullin B, Nation N, Church JS, Dorin C, Miller C. Non-inferiority of Nitric Oxide Releasing Intranasal Spray Compared to Sub-therapeutic Antibiotics to Reduce Incidence of Undifferentiated Fever and Bovine Respiratory Disease Complex in Beef Cattle Arriving at a Commercial Feedlot 2015; DOI 10.1016/j.prevetmed.2015.04.008

Miller C. Nitric Oxide: Potential Therapeutic Role in CF Lung Disease. Pediatric Pulmonology 2014;10(suppl 38):181-182.

Regev-Shoshani, G., Vimalanathan, S., Prema, D., Church, J.S., Reudink, M.W., Nation, N., Miller, C. Safety, Bioavailability and Mechanism of Action of Nitric Oxide to Control Bovine Respiratory Disease Complex in Calves Entering a Feedlot, Research in Veterinary Science (2013), doi: http://dx.doi.org/10.1016/j.rvsc.2014.12.012

Regev-Shoshani G, Crowe A, Miller C. Nitric Oxide Eradicates Mycelia and Conidia of Trichophyton Rubrum and Trichophyton Mentagrophytes in-vitro . Journal of Applied Microbiology. 2013: 114, 536—544. doi:10.1111/jam.12047

Regev-Shoshani G, Crowe A, Miller C. Nitric Oxide Eradicates Mycelia and Conidia of Trichophyton Rubrum and Trichophyton Mentagrophytes in-vitro . Journal of Applied Microbiology. 2013: 114, 536—544. doi:10.1111/jam.12047

Miller CC, Hergott CA, Rohan M, Arsenault-Mehta K, Doering G , Mehta S. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J Cyst Fibrosis 2013; 10.1016/j.jcf.2013.01.008.

Regev-Shoshani G, Church JS, Cook NJ, Schaefer AL, Miller C. Prophylactic Nitric Oxide Treatment Reduces Incidence of Bovine Respiratory Disease Complex in Beef Cattle Arriving at a Feedlot. Research in Veterinary Science. Doi: 10.1016/j.rvsc.2013.06.016

Darwish I, Miller C, Kain K, Conrad Liles WC. Inhaled Nitric Oxide Therapy Fails to Improve Outcome in Experimental Severe Influenza. Int. J. Med. Sci. 2012; 9(2):157-162. doi: 10.7150/ijms.3880.

Hawkes M, Opika Opoka R, Namasopo S, Miller C, Conroy AL, Serghides L, Kim H, Thampi N, Liles WC, John CC, Kain KC. Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale. Med Hypotheses 2011;77(3):437-44.

Miller C, Miller M, McMullin B, Regev G, Serghides L, Kain K, Road J, Av-Gay Y. Results of a phase I clinical study: evaluation of safety of 160ppm nitric oxide given intermittently via inhalation to healthy adults volunteers. J Cyst Fibrosis 2012;11:324-331, doi:10.1016/j.jcf.2012.01.003.

Hawkes M, Robert, Opoka RO, Namasopo S, Miller C,Thorpe KE, Lavery JV, Conroy AL, Liles C, John CC, Kain KC. Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: Protocol for a Randomized Controlled Trial. Trials 2011;12(1):176-189.

Serghides L, Kim H, Lu Z, Kain DC, Miller C, Francis RC, Liles C, Zapol WM, Kain KC. Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and protects against murine cerebral malaria. PLoS ONE 6(11): e27714. doi:10.1371/journal. pone.0027714

Rezakhanloua, A, Miller C, McMullin B, Ghaffaria A, Ghaharya A. Gaseous Nitric Oxide Exhibits Does Not Effect Skin Fibroblast Extra Cellular Matrix Gene Expression and Immune Cell Viability. Cell Biol Int 2011;35:407-415.

Regev-Shoshani G , Ko M, Miller C, Av-Gay Y. The slow release of Nitric Oxide from charged catheter and its antimicrobial effect on Escherichia coli Antimicrobial Agents And Chemotherapy 2010;54(1):273-279.

Darwish I, Miller C, Kain K, Conrad Liles WC. Inhaled Nitric Oxide Therapy Fails to Improve Outcome in Experimental Severe Influenza. Int. J. Med. Sci. 2012; 9(2):157-162. doi: 10.7150/ijms.3880.

Non-refereed Publications

Conference proceedings

Miller C. Nitric Oxide: Potential Therapeutic Role in CF Lung Disease. Pediatric Pulmonology 2014;10(suppl 38):181-182.

Abstracts

Miller CC. Effects of gaseous nitric oxide on the reduction of bacterial load in porcine and human bacterial positive ulcers and lesions. Poster at World Congress of Wound Healing, Denver, May 2013.

Regev G, Miller et al. Gaseous nitric oxide reduces infection levels of Influenza H3N2, H1N1 and Influenza B strains in an ex vivo MDCK Cell Model. Oral Presentation, ATS, San Francisco,  May 2012.

Miller C et al. Gaseous nitric oxide: a potential broad spectrum inhaled antimicrobial agent. Poster Presentation, ATS, San Francisco, May 2012.

Rizzo N, Arana B, Gramajo R, Grog RM, Magill AJ, Miller C. An open-label pilot trial of topical gaseous nitric oxide for treatment of cutaneous leishmaniasis in Guatemala. Poster ASTMH December 6, 2011.

Miller C. Nitric Oxide: A Potential First Line Antimicrobial Agent or as an Adjuvant to Antibiotics. CIHR Young Investigator Forum, Oct 14-16, 2011 Quebec City, Quebec Canada.

Regev-Shoshani G , Ko M, Miller C, Av-Gay Y. The slow release of Nitric Oxide from charged catheter and its antimicrobial effect on Escherichia coli. (abstract) Antimicrobial. ICAAC, San Francisco Sept 15, 2009

Miller, C, McMullin, Rimkus, M, Stenzler, A., Av-Gay Y, Road, J. Methemoglobin production in normal adults inhaling intermittent high concentrations of nitric oxide (abstract). Resp Care 2008; 53(11):1530.

Miller, C, McMullin, B, Ghaffari, A, Pick, N, Stenzler, A, Ghahary, A, Roscoe, D, Road, J, Av-gay, Y. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. (abstract). Resp Care 2008; 53(11):1530.

Miller CC, Boegli L, McMullin B, James GA, Carr NJ, Av-Gay Y. Effective Treatment of Graft Rejection by Gaseous Nitric Oxide Secondary to MRSA Refractory to Vancomycin. World Congress of Wound Healing, Toronto, July 2008.

Miller CC, McMullin BB, Dimond S, Meredith SR, Morley RM, Boyle JC, Carr NJ. Nitric Oxide Gas (gNO): A Potential New Antimicrobial Therapy for Multi-Drug Resistant Wounds. American Burn Conference, San Diego. March 2007.

Miller C, McMullin B, Road J, Av-Gay Y. Supraphysiologic Exogenous Gaseous Nitric Oxide: Potential treatment for respiratory infections. International Consortium on Anti-Virals Fifth Symposium, May 2007 – Abuja, Nigeria.

Miller CC. Just say NO (Nitric Oxide)  to Bioflims. 8th Annual “Wound Healing: Science and Industry.” Montana State University. December 13-16, 2007.

Patents

US 7,485,324 Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms.

US 7,955,294; US 8,043,252 Intermittent Dosing of Nitric Oxide

US 7,122,018, US 6,668,828 Device and method for treatment of wounds with nitric oxide.

US 6,986,351 System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient.

US 6,955,171 System and method for delivering therapeutic gas to a patient.

US 6,920,876 Device for administration of nitric oxide to horses

US 7,335,181 Nitric oxide decontamination of the upper respiratory tract.

2003 0150457 Device for administration of nitric oxide to horses spontaneously breathing.

2004 0009238 Exogenous nitric oxide gas (gNO) therapy in wound healing.

2005 0191372 Device and method for treatment of wounds with nitric oxide.

2006 0147553 Method and apparatus for treatment of respiratory infections by nitric oxide inhalation.

2006 0207594 Method and apparatus for delivery of inhaled nitric oxide to a spontaneous breathing and mechanically-ventilated patients with intermittent dosing.

2006 0068031 Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms.

2007 0014688 Use of nitric oxide un an extracorporeal circuitry to treat blood plasma.

2007 TBA Use of nitric oxide gas to treat blood and blood products.

2007 TBA Topical nitric oxide as a treatment of autoimmune diseases.

2008 TBA Prevention of host-to-host transmission of virions.

2008 TBA Embedded nitric oxide-generating anti-septic dressings.

2008 TBA Method of treating an infection with nitric oxide and oxygen.

 

a place of mind, The University of British Columbia

© Copyright 2009, Immunity and Infection Research Centre

Emergency Procedures | Accessibility | Contact UBC  | © Copyright The University of British Columbia